JULY 1st, 2024
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of
JUNE 25, 2024
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all
JUNE 20, 2024
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million Biophytis announces the signature of an exclusive
JUNE 19, 2024
Biophytis extends its contract with Atlas to secure financing for its business activities Biophytis announces the extension of its bond financing agreement with Atlas, a
JUNE 12, 2024
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for
JUNE 10, 2024
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an
JUNE 7, 2024
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université –
MAY 14, 2024
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in
APRIL 29, 2024
Biophytis is deploying its partnership strategy in obesity Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working
APRIL 24, 2024
Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company